Shandong Lukang Pharmaceutical Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000000P61
CNY
9.82
0.02 (0.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
6,178.51
6,092.96
5,570.26
4,885.74
4,167.49
3,703.51
3,287.05
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
6,178.51
6,092.96
5,570.26
4,885.74
4,167.49
3,703.51
3,287.05
Raw Material Cost
4,840.04
4,725.27
4,450.68
3,816.20
3,286.83
2,723.43
2,335.79
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
75.38
79.17
104.88
69.57
65.52
59.60
45.30
Selling and Distribution Expenses
751.54
747.56
660.38
660.67
594.61
671.93
647.06
Other Expenses
20.56
22.75
13.05
16.55
9.82
6.20
6.41
Total Expenditure (Excl Depreciation)
5,872.51
5,779.46
5,346.46
4,711.90
4,045.16
3,516.96
3,092.28
Operating Profit (PBDIT) excl Other Income
306
313.5
223.79999999999998
173.79999999999998
122.30000000000001
186.5
194.8
Other Income
223.53
81.89
69.19
31.57
212.51
33.47
73.52
Operating Profit (PBDIT)
918.20
741.62
610.55
495.41
569.97
381.16
390.93
Interest
75.38
79.17
104.88
69.57
65.52
59.60
45.30
Exceptional Items
0.76
0.26
1.04
0.74
0.71
13.14
2.76
Gross Profit (PBDT)
1,338.48
1,367.70
1,119.57
1,069.54
880.66
980.08
951.26
Depreciation
402.01
382.57
350.00
309.71
245.48
188.80
159.22
Profit Before Tax
441.57
280.14
156.71
116.87
259.68
145.90
189.17
Tax
25.55
16.19
6.98
23.69
28.68
20.03
18.88
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
394.62
246.17
138.01
89.10
227.88
121.25
161.39
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
394.62
246.17
138.01
89.10
227.88
121.25
161.39
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
13.73
10.62
5.10
0.79
5.61
7.54
12.05
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
408.35
256.79
143.11
89.89
233.48
128.79
173.43
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
3,918.19
3,611.70
3,356.86
3,282.96
3,213.98
3,021.16
2,925.90
Earnings per share (EPS)
0.44
0.27
0.15
0.1
0.25
0.14
0.19
Diluted Earnings per share
0.44
0.27
0.15
0.1
0.25
0.14
0.19
Operating Profit Margin (Excl OI)
4.74%
4.55%
3.44%
3.15%
2.69%
4.29%
4.81%
Gross Profit Margin
13.65%
10.88%
9.1%
8.73%
12.12%
9.04%
10.6%
PAT Margin
6.39%
4.04%
2.48%
1.82%
5.47%
3.27%
4.91%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 1.40% vs 9.38% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 59.00% vs 79.45% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 5.31% vs 21.85% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -4.80% vs -24.50% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Shandong Lukang Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
6,178.51
0
6,178.51
Other Operating Income
0.00
0.00
0.00
Total Operating income
6,178.51
0
6,178.51
Raw Material Cost
4,840.04
0
4,840.04
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
75.38
0
75.38
Selling and Distribution Expenses
751.54
0
751.54
Other Expenses
20.56
0.00
20.56
Total Expenditure (Excl Depreciation)
5,872.51
0
5,872.51
Operating Profit (PBDIT) excl Other Income
306.00
0.00
306.00
Other Income
223.53
0
223.53
Operating Profit (PBDIT)
918.20
0
918.20
Interest
75.38
0
75.38
Exceptional Items
0.76
0
0.76
Gross Profit (PBDT)
1,338.48
0
1,338.48
Depreciation
402.01
0
402.01
Profit Before Tax
441.57
0
441.57
Tax
25.55
0
25.55
Provisions and contingencies
0
0
0.00
Profit After Tax
394.62
0
394.62
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
394.62
0
394.62
Share in Profit of Associates
0
0
0.00
Minority Interest
13.73
0
13.73
Other related items
0.00
0.00
0.00
Consolidated Net Profit
408.35
0
408.35
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
3,918.19
0
3,918.19
Earnings per share (EPS)
0.44
0
0.44
Diluted Earnings per share
0.44
0
0.44
Operating Profit Margin (Excl OI)
4.74%
0%
0.00
4.74%
Gross Profit Margin
13.65%
0%
0.00
13.65%
PAT Margin
6.39%
0%
0.00
6.39%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 617.85 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 1.40% vs 9.38% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 40.83 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 59.00% vs 79.45% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 69.47 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 5.31% vs 21.85% in Dec 2023

Annual - Interest
Interest 7.54 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -4.80% vs -24.50% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 4.74%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023